Gannet BioChem and Re-Vana Therapeutics Enter Development and cGMP Supply Agreement to Support Ophthalmic Drug Delivery Program
Financial Post ·
The agreement supports EyeLief® combination drug-device product development in anticipation of a future clinical program, with polymer supply also supporting OcuLief® and non-ocular applications HUNTSVILLE, Ala., Oct. 27, 2026 (GLOBE NEWSWIRE) — Gannet BioChem, a specialized contract development and manufacturing organization (CDMO) focused on activated polymers and bioconjugation, and Re-Vana Therapeutics, a biotechnology company developing […]
The agreement supports EyeLief® combination drug-device product development in anticipation of a future clinical program, with polymer supply also supporting OcuLief® and non-ocular applications Read More